Evidence / D'Anna et al. · 2007
Genistein in a postmenopausal trial
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, double-blind, placebo-controlled human trial.
- Product relevance
- Ingredient evidence from a different genistein intervention.
- Sample or population
- 389 women were randomized. Hot flushes were evaluated in a subgroup of 247.
- Studied dose
- 54 mg/day of genistein or placebo.
- Duration
- 12 months.
- Finding
- The authors reported lower hot-flush frequency and severity with genistein in the subgroup. Endometrial thickness and the vaginal maturation measure did not significantly differ between groups.
- Limitations
- Symptom analysis was limited to a subgroup, and this dose and intervention differ from the DR.MORGAN formula.
- Study quality
- Placebo-controlled design with subgroup symptom analysis. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.